Peripheral neuropathy and cancer
- 1 January 2004
- journal article
- review article
- Published by Springer Nature in Current Oncology Reports
- Vol. 6 (1) , 20-25
Abstract
Peripheral neuropathy has a major impact on quality of life and may limit the amount of treatment patients can receive. Neurotoxic agents are used increasingly in oncologic practice, yet clinicians are often unaware of the protean manifestations of neuropathy and find its management troubling. Recent knowledge about the mechanisms of neuropathic disease and new treatments may help to minimize the impact of neuropathy on this vulnerable patient population.Keywords
This publication has 53 references indexed in Scilit:
- Antidepressants and Anticonvulsants for Diabetic Neuropathy and Postherpetic NeuralgiaJournal of Pain and Symptom Management, 2000
- Anticonvulsants for Neuropathic Pain SyndromesDrugs, 2000
- Comparative Neurotoxicity of Oxaliplatin, Cisplatin, and Ormaplatin in a Wistar Rat Model,Toxicological Sciences, 1998
- NGF prevention of neurotoxicity induced by cisplatin, vincristine and taxol depends on toxicity of each drug and NGF treatment schedule:Brain Research, 1998
- Treatment of cancer chemotherapy-induced toxicity with the pineal hormone melatoninSupportive Care in Cancer, 1997
- Stimulation of endometrial cancer cell growth by tamoxifen is associated with increased insulin-like growth factor (IGF)-I induced tyrosine phosphorylation and reduction in IGF binding proteinsEndocrinology, 1996
- EXPERIENCE WITH REHABILITATION IN THE ACQUIRED IMMUNODEFICIENCY SYNDROMEAmerican Journal of Physical Medicine & Rehabilitation, 1991
- Thalidomide neuropathy: An electrophysiologic studyMuscle & Nerve, 1986
- Thalidomide neurotoxicityArchives of Dermatology, 1984
- Some features of the neuromuscular complications of pulmonary carcinomaAnnals of Neurology, 1977